Extended Oral Tranexamic Acid After Anterior Cruciate Ligament Reconstruction

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2027

Conditions
ACL InjuryACL TearsACL Surgery
Interventions
DRUG

Tranexamic Acid (TXA)

Oral tranexamic acid (TXA) is administered at a dose of 1.95 grams per day, divided into three 650 mg capsules taken once daily, starting on postoperative day (POD) 1 through POD 10 (10 total doses; 30 capsules) to the treatment group.

DRUG

Placebo

Participants in this arm will receive oral placebo capsules (microcrystalline cellulose), 3 capsules daily from postoperative day (POD) 1 to POD 10, for a total of 10 doses (30 capsules).

Trial Locations (6)

15260

University of Pittsburgh, Pittsburgh

27705

Duke University School of Medicine, Durham

38138

Campbell Clinic, Germantown

45221

University of Cincinnati, Cincinnati

60201

Endeavor Health, Evanston

63017

Washington University School of Medicine in St. Louis, Chesterfield

Sponsors
All Listed Sponsors
collaborator

Duke University

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

Endeavor Health

OTHER

collaborator

University of Cincinnati

OTHER

collaborator

Washington University School of Medicine

OTHER

lead

Campbell Clinic

OTHER